Contaminated heparin

New England Journal of Medicine

Volumn 359, Issue 12, 2008, Pages 1291-1293

  Greinacher, Andreas ^a   Warkentin, Theodore E ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; HEPARIN;

ANAPHYLAXIS; DRUG CONTAMINATION; DRUG DISTRIBUTION; DRUG FATALITY; DRUG SULFATION; DRUG SURVEILLANCE PROGRAM; HUMAN; LETTER; PRIORITY JOURNAL; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COMPLEMENT ACTIVATION; DRUG EFFECT; NOTE;

ANAPHYLAXIS; CHONDROITIN SULFATES; COMPLEMENT ACTIVATION; DRUG CONTAMINATION; HEPARIN; HUMANS; THROMBOCYTOPENIA;

EID: 52249107324     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc081387     Document Type: Letter

References (5)

1. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358:2457-67.
2. Greinacher A, Michels I, Schäfer M, Kiefel V, Mueller-Eckhardt C. Heparin-associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate: evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan. Br J Haematol 1992;81:252-4.
3. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunologic type of heparin-associated thrombocytopenia. Thromb Haemost 1995;74:886-92.
4. Warkentin TE. Drug-induced immune-mediated thrombocytopenia - from purpura to thrombosis. N Engl J Med 2007;356: 891-3.
5. Warkentin TE, Greinacher A, eds. Heparin-induced thrombucytopenia. 4th ed. New York: Informa Healthcare USA, 2007.